Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volulyte vs Plasmalyte GDFT in Major Abdominal Surgery
NCT02312999Phase 4Completed
- Sponsor
- CHU Brugmann
- Start
- Feb 2015
- Primary completion
- Dec 2017
- Modality
- Polymer-based Nanoparticles, Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hetastarch in hypovolemia (2 arms), sponsored by CHU Brugmann. Primary endpoint: Postoperative Morbidity Survey Score at 48 hours. Started Feb 2015; status: completed.
02
Drugs
hetastarch
03
Conditions
hypovolemia
Beyond the preview
Go deeper on NCT02312999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02312999.